ReviewNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026
Unravelling the novel insights between miR-7 and Parkinson's disease (PD).
Review in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting the non-coding RNA-PANoptosis axis: a novel frontier in disease diagnosis and therapy.Apoptosis : an international journal on programmed cell death · 2026Review
- MiR-7 in neurological disorders: beyond metabolic dysregulation.Frontiers in neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Background:miR-7, a short non-coding RNA (ncRNA), has been implicated in molecular pathways associated with Parkinson’s Disease (PD) pathogenesis by regulating the expression of genes, including SNCA, which encodes the α-Synuclein (α-Syn) protein. PD, the second most common neurodegenerative disorder, has a multifactorial origin involving gene mutations, lifestyle factors, and inflammation. A hallmark of PD is the abnormal expression of SNCA, leading to α-Syn protein deposition in dopaminergic neurons. Mechanisms and Functional Roles:miR-7 regulates SNCA expression by binding to the 3’UTR of SNCA mRNA, and altered miR-7 levels have been associated with changes in SNCA protein expression. Additionally, miR-7 influences Brain Derived Neurotrophic Factor (BDNF), vital for dopaminergic neuron development and maintenance. The relationship between miR-7 and BDNF is complex, as miR-7 regulates BDNF indirectly through SNCA. Moreover, miR-7 is involved in the PI3K/AKT/mTOR signaling pathway, significant in PD pathogenesis. However, all the evidences of miR-7 being a master regulator comes mostly from animal and cell studies with limited human studies. Beyond its pathological role, miR-7 is essential for neuron and mitochondrial function, and its role in normal brain activity. Conclusion: This review highlights miR-7 associated regulatory mechanisms involved in PD pathogenesis, emphasizing its regulatory role, neuroprotective functions, participation in signaling pathways, and therapeutic potential. Understanding miR-7’s mechanisms offer insight into its role in PD and its prospects for targeted interventions.
Indexed as
Identifiers
41762282What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.